Cargando…

Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms

BACKGROUND: Programmed death 1/programmed death ligand 1 (PD-1/PD-L1) targeted immunotherapy affords clinical benefit in ~20% of unselected patients with lung cancer. The factor(s) that determine whether a tumor responds or fails to respond to immunotherapy remains an active area of investigation. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neuwelt, Alexander J, Kimball, Abigail K, Johnson, Amber M, Arnold, Benjamin W, Bullock, Bonnie L, Kaspar, Rachael E, Kleczko, Emily K, Kwak, Jeff W, Wu, Meng-Han, Heasley, Lynn E, Doebele, Robert C, Li, Howard Y, Nemenoff, Raphael A, Clambey, Eric T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204826/ https://www.ncbi.nlm.nih.gov/pubmed/32312906 http://dx.doi.org/10.1136/jitc-2019-000441

Ejemplares similares

Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti–PD-1 response in NSCLC
por: Bullock, Bonnie L, et al.
Publicado: (2019)

Eicosanoids in Cancer: New Roles in Immunoregulation
por: Johnson, Amber M., et al.
Publicado: (2020)

Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer
por: Kleczko, Emily K., et al.
Publicado: (2019)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
por: Kleczko, Emily K., et al.
Publicado: (2023)

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities
por: Kleczko, Emily K., et al.
Publicado: (2018)

ATRT-02. MEK/ERK SIGNALLING DEPENDENCY IN ATYPICAL TERATOID RHABDOID TUMOURS
por: Shi, Hui (Claire), et al.
Publicado: (2020)

Salivary Estrogens Androgens and Aromatase Inhibitors by LC-MS/MS in Breast Cancer Patients Treated With Testosterone Pellets Combined With Aromatase Inhibitors
por: Zava, David T, et al.
Publicado: (2021)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
por: Zhang, Biying, et al.
Publicado: (2023)

The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression
por: Nguyen, Dustin T., et al.
Publicado: (2023)

A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes
por: Schubert, Laura, et al.
Publicado: (2023)

Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells
por: Neo, Shi Yong, et al.
Publicado: (2022)

CD8(+) T cells modulate autosomal dominant polycystic kidney disease progression
por: Kleczko, Emily K., et al.
Publicado: (2018)

A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes
por: Schubert, Laura, et al.
Publicado: (2023)

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
por: Molvi, Zaki, et al.
Publicado: (2023)

Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response
por: Korpela, Sean P., et al.
Publicado: (2021)

IL1R2 increases regulatory T cell population in the tumor microenvironment by enhancing MHC-II expression on cancer-associated fibroblasts
por: Chen, Lujun, et al.
Publicado: (2022)

Role of MEK partner-1 in cancer stemness through MEK/ERK pathway in cancerous neural stem cells, expressing EGFRviii
por: Kwon, Soo-Jung, et al.
Publicado: (2017)

The MEK/ERK Pathway Promotes NOTCH Signalling in Pancreatic Cancer Cells
por: Tremblay, Isabelle, et al.
Publicado: (2013)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

Upregulation of complement proteins in lung cancer cells mediates tumor progression
por: Kleczko, Emily K., et al.
Publicado: (2023)

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
por: Gurule, Natalia J., et al.
Publicado: (2021)

THU484 Distinct Genetic Characteristics In Follicular Thyroid Cancer With Different Metastatic Potentials
por: Kwak, Soo-jung, et al.
Publicado: (2023)

Pelvic irradiation does not increase the risk of hip replacement in patients with gynecological cancer: A cohort study based on 8,507 patients
por: Dybvik, Eva, et al.
Publicado: (2014)

Targeting the coding sequence: opposing roles in regulating classical and non-classical MHC class I molecules by miR-16 and miR-744
por: Friedrich, Michael, et al.
Publicado: (2020)

RARE-18. NF1-MUTATED TUMORS EXHIBIT INCREASED SENSITIVITY TO AUTOPHAGY INHIBITION ALONE AND IN COMBINATION WITH MEK INHIBITION
por: Baird-Daniel, Eliza, et al.
Publicado: (2021)

MEK/ERK addiction in CNL/aCML
por: Kesarwani, Meenu, et al.
Publicado: (2017)

Netrin-1 suppresses the MEK/ERK pathway and ITGB4 in pancreatic cancer
por: An, Xi-Zhou, et al.
Publicado: (2016)

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression
por: Franklin, Derek A., et al.
Publicado: (2020)

Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation
por: Deng, Guoliang, et al.
Publicado: (2022)

Computer-assisted surgery in orthopedic oncology: Technique, indications, and a descriptive study of 130 cases
por: Gerbers, Jasper G, et al.
Publicado: (2014)

KIF15 promotes bladder cancer proliferation via the MEK–ERK signaling pathway
por: Zhao, Hongda, et al.
Publicado: (2019)

KIF15 promotes pancreatic cancer proliferation via the MEK–ERK signalling pathway
por: Wang, Jie, et al.
Publicado: (2017)

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
por: Nickols, Nicholas G., et al.
Publicado: (2019)

BCKDK Promotes Ovarian Cancer Proliferation and Migration by Activating the MEK/ERK Signaling Pathway
por: Li, Huashun, et al.
Publicado: (2022)

TTYH3 Modulates Bladder Cancer Proliferation and Metastasis via FGFR1/H-Ras/A-Raf/MEK/ERK Pathway
por: Biswas, Polash Kumar, et al.
Publicado: (2022)

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
por: Davis, Thomas B., et al.
Publicado: (2019)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
por: Wu, Pui-Kei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m43q96sbbfvf9pmgmollub99l2